Showing 1 - 20 results of 49 for search '(( ct ((largest decrease) OR (marked decrease)) ) OR ( mpa mean decrease ))', query time: 0.41s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Data Sheet 1_Empagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure.pdf by Hua Wei (60877)

    Published 2025
    “…Post-treatment, MRGlu and glucose uptake decreased markedly in the empagliflozin (EMPG) group, while no significant changes were observed in the fenofibrate (FF) group. …”
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    (A-H). Case 1: primary subcutaneous facial alveolar echinococcosis. by Louis Bohard (22250661)

    Published 2025
    “…<p><b>(A)</b> Left frontal swelling at diagnosis. <b>(B)</b> Marked regression of the lesion after 6 months of albendazole therapy. …”
  15. 15

    Data Sheet 2_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysi... by Jiahui Qiu (7420130)

    Published 2025
    “…Subgroup and sensitivity analyses were performed to explore heterogeneity, and publication bias was assessed using Egger's test and trim-and-fill methods.</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  16. 16

    Data Sheet 1_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysi... by Jiahui Qiu (7420130)

    Published 2025
    “…Subgroup and sensitivity analyses were performed to explore heterogeneity, and publication bias was assessed using Egger's test and trim-and-fill methods.</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  17. 17

    Table 1_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysis of... by Jiahui Qiu (7420130)

    Published 2025
    “…Subgroup and sensitivity analyses were performed to explore heterogeneity, and publication bias was assessed using Egger's test and trim-and-fill methods.</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  18. 18

    Table 2_The effects of oral medroxyprogesterone acetate combined with conjugated equine estrogens on inflammation in postmenopausal women: a systematic review and meta-analysis of... by Jiahui Qiu (7420130)

    Published 2025
    “…Subgroup and sensitivity analyses were performed to explore heterogeneity, and publication bias was assessed using Egger's test and trim-and-fill methods.</p>Results<p>MPA/CEE treatment was associated with a significant decrease in CRP levels (WMD = -0.173 mg/dL; 95% CI: -0.25 to -0.10; P < 0.001), particularly among postmenopausal women aged <60 years, trials with MPA doses ≤2.5 mg/day, and those with BMI <25 kg/m². …”
  19. 19

    Table1_Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data.DOCX by Luyang Su (20411552)

    Published 2025
    “…Disproportionality analyses were conducted using several statistical methods, including reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayesian geometric mean (EBGM). Additionally, time-to-onset (TTO) analysis was employed to quantify the signals of the MPA-associated AEs.…”
  20. 20

    Table1_Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data.DOCX by Luyang Su (20411552)

    Published 2024
    “…Disproportionality analyses were conducted using several statistical methods, including reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayesian geometric mean (EBGM). Additionally, time-to-onset (TTO) analysis was employed to quantify the signals of the MPA-associated AEs.…”